Compounding pharmacies argue that their ability to create imitations of tirzepatide drugs was crucial when supplies were low, providing essential alternatives for patients with diabetes and obesity. As the FDA previously classified tirzepatide as being in short supply, the demand surged, resulting in many patients struggling to obtain their prescriptions. The FDA's recent announcement of stability in the drug's supply chain has led to a cessation of these imitations, putting added pressure on patients accustomed to these custom formulations.
The FDA confirmed that the domestic supply of tirzepatide has stabilized, citing direct communication with the drug's manufacturer, Eli Lilly. They assured that current manufacturing capacities align with anticipated nationwide demand. While this resolution is seen as a positive development for patients previously facing shortages, the FDA cautioned that localized supply disruptions may still occur, affecting how readily available these essential diabetes medications will be.
Collection
[
|
...
]